Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular FeaturesWalid Macaron, Nicholas J. Short, Jairo Matthews et al.|Blood|2024Cited by 5
Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 StudyHannah Goulart, Hagop Kantarjian, Farhad Ravandi et al.|Blood|2025Cited by 2